Belevskiy A S, Nenasheva N M, Kravchenko N Y, Makar'iants N N, Kuntsev D A
Pirogov Russian National Research Medical University.
Russian Medical Academy of Continuous Professional Education.
Ter Arkh. 2022 Aug 12;94(7):865-871. doi: 10.26442/00403660.2022.07.201713.
Creation of the "Russian register of patients with severe asthma" and obtaining data on the population characteristics of patients with severe asthma (SA), the prevalence of SA phenotypes, treatment outcomes and the degree of disease control.
Observational non-interventional study, which consists in the data analysis obtained on the basis of registration cards of the Russian Register of Patients with Severe Bronchial Asthma, data collection in which was carried out on the Oracle XE platform. Statistical data processing was carried out using Power BI, PSPP and Microsoft Excel spreadsheets.
The study included 4376 adult patients (mean age 60.613.5 years, 65% women) diagnosed with SA from 57 regions of Russia for the period from June 2018 to December 2021. T2 inflammation was detected in 94.8% of patients when determining blood eosinophils and IgE of blood serum; 69% of patients with SA corresponded to the allergic phenotype. 83.3% of patients had no control of BA and 53% had 1 or more exacerbations of BA per year. 8% of patients received systemic corticosteroids as a permanent therapy, while biologics 10.6%.
The vast majority of adult patients with SA correspond to the T2 phenotype, have uncontrolled asthma with a high frequency of exacerbations and reduced lung function. A more favorable course of the disease was noted in patients receiving biological therapy, which requires appropriate measures to increase the possibility of access to this type of therapy.
创建“俄罗斯重症哮喘患者登记册”，并获取重症哮喘（SA）患者的人口统计学特征、SA表型患病率、治疗结果和疾病控制程度的数据。
观察性非干预研究，包括对基于俄罗斯重症支气管哮喘患者登记册登记卡获得的数据分析，数据收集在Oracle XE平台上进行。使用Power BI、PSPP和Microsoft Excel电子表格进行统计数据处理。
该研究纳入了2018年6月至2021年12月期间来自俄罗斯57个地区的4376名成年SA患者（平均年龄60.6±13.5岁，65%为女性）。在测定血清嗜酸性粒细胞和IgE时，94.8%的患者检测到2型炎症；69%的SA患者符合过敏表型。83.3%的患者哮喘未得到控制，53%的患者每年有1次或更多次哮喘发作。8%的患者接受全身糖皮质激素作为长期治疗，而接受生物制剂治疗的患者为10.6%。
绝大多数成年SA患者符合2型表型，哮喘未得到控制，发作频率高且肺功能下降。接受生物治疗的患者疾病进程更有利，这需要采取适当措施增加获得此类治疗的可能性。
